Indications
For adult patients treated with a direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
Composition
- Active substance
- andexanet alfa
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Ondexxya
- Active substance
- andexanet alfa
- ATC code
- V03AB
- Group
- Various
- Therapeutic area
- Drug-Related Side Effects and Adverse Reactions
- Marketing authorisation holder
- AstraZeneca AB
- Status
- Authorised
- EU authorisation
- 26 Apr 2019